Surgery Partners stock hits 52-week low at 19.49 USD

Surgery Partners Inc (NASDAQ:SGRY). stock has reached a new 52-week low, closing at $19.49. According to InvestingPro analysis, the stock’s RSI indicates oversold territory, potentially signaling a technical bottom for this $2.49 billion market cap healthcare services provider. This marks a significant decline for the healthcare services company, which has seen its stock price fall by 20.05% over the past year, despite posting robust revenue growth of ~14%. The drop reflects ongoing challenges in the sector and investor concerns about future growth prospects, though InvestingPro data shows analyst price targets ranging from $24 to $36, suggesting potential upside. Get access to 8 more exclusive InvestingPro Tips and comprehensive analysis in the Pro Research Report. As the stock hits this new low, market analysts are closely monitoring Surgery Partners’ performance and strategic initiatives to gauge potential recovery or further declines in the coming months. With a beta of 1.94, investors should note the stock’s higher volatility compared to the broader market. Based on InvestingPro’s Fair Value analysis, the stock appears fairly valued at current levels.

In other recent news, Surgery Partners announced the conclusion of acquisition talks with Bain Capital, deciding to remain an independent publicly traded company. The Special Committee of independent directors determined that Surgery Partners’ future prospects as an independent entity outweighed Bain Capital’s proposal. CEO Eric Evans reaffirmed the company’s full-year 2025 guidance, projecting revenues between $3.30 billion and $3.45 billion, and Adjusted EBITDA between $555 million and $565 million. UBS has reiterated its Buy rating for Surgery Partners with a price target of $34.00, following the company’s rejection of Bain Capital’s acquisition offer. UBS noted that Surgery Partners has consistently demonstrated strong growth, with a 14.5% compound annual growth rate for adjusted EBITDA between 2019 and 2024. Surgery Partners recently held its annual stockholders’ meeting, where key proposals, including the election of Class I directors and the approval of the 2025 Omnibus Incentive Plan, were passed. Additionally, the ratification of Ernst & Young LLP as the independent registered public accounting firm for 2025 was approved. Surgery Partners plans to host an Investor Day in the second half of 2025 to discuss its strategy and outlook.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.